ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Evaluation of resistance mechanisms and susceptibility testing in Enterococcus spp.: implications of vancomycin-variable isolates and optrA-mediated resistance.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVancomycin-resistant enterococci (VRE) represent a major challenge in healthcare settings due to limited therapeutic options and the emergence of resistance to last-line agents. Accurate detection of resistance mechanisms and understanding the molecular epidemiology of circulating strains are essential for effective surveillance and infection control.
methodsA total of 192 non-duplicate Enterococcus isolates (103 VRE and 89 vancomycin-susceptible isolates) recovered from clinical specimens between 2018 and 2022 were analyzed. Antimicrobial susceptibility testing was performed using broth microdilution (BMD) as the reference method and compared with automated and gradient-based methods. Resistance genes associated with vancomycin and linezolid resistance were investigated by in-house PCR and sequencing. Clonal relatedness of VRE isolates was assessed using AP-PCR, PFGE, and MLST.
resultsAmong VRE isolates, vanA was the predominant resistance determinant, while a single isolate carried vanB. Importantly, vanA was also detected in three phenotypically vancomycin-susceptible E. faecalis isolates, consistent with vancomycin-variable enterococci. Linezolid resistance was identified in three isolates (1.6%); two E. faecalis isolates harbored the transferable optrA gene, representing the first report of optrA-positive E. faecalis causing human infections in Türkiye, while one E. faecium isolate showed linezolid resistance in the absence of the investigated resistance genes. Tigecycline resistance was uncommon. Daptomycin retained in vitro activity with higher MIC₅₀/ MIC₉₀ values in E. faecium, whereas oritavancin MIC values were higher among E. faecalis isolates. The BD Phoenix system demonstrated high categorical agreement with BMD for vancomycin and teicoplanin but generated major and very major errors for linezolid susceptibility testing. Molecular typing revealed extensive genetic diversity among VRE isolates, with 35 AP-PCR genotypes, PFGE-confirmed clustering including one predominant clone, and the identification of 11 novel MLST sequence types (ST2994-ST3004).
conclusionsThis study provides insight into the resistance landscape and genetic diversity of clinical Enterococcus isolates. The detection of vancomycin-variable enterococci and transferable linezolid resistance determinants underscores the need for integrated phenotypic and molecular approaches to ensure accurate resistance detection and effective surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.